Open AccessDisclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment
Author(s) -
Christensen Kurt D.,
Karlawish Jason,
Roberts J. Scott,
Uhlmann Wendy R.,
Harkins Kristin,
Wood Elisabeth M.,
Obisesan Thomas O.,
Le Lan Q.,
Cupples L. Adrienne,
Zoltick Emilie S.,
Johnson Megan S.,
Bradbury Margaret K.,
Waterston Leo B.,
Chen Clara A.,
Feldman Sara,
Perry Denise L.,
Green Robert C.
Publication year - 2020
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12002
Subject(s) - dementia , anxiety , depression (economics) , clinical psychology , randomized controlled trial , alzheimer's disease , psychiatry , cognition , confidence interval , psychology , medicine , disease , economics , macroeconomics
The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E ( APOE ) genotyping is unknown. Methods We randomized 114 individuals with MCI to receive estimates of 3‐year risk of conversion to AD dementia informed by APOE genotyping (disclosure arm) or not (non‐disclosure arm) in a non‐inferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary outcomes included other psychological measures. Results Upper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non‐inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm than non‐disclosure arm for test‐related positive impact (difference: ‐1.9, indicating more positive feelings) and AD concern (difference: ‐0.3). Discussion Providing genetic information to individuals with MCI about imminent risk for AD does not increase risks of anxiety or depression and may provide psychological benefits.